Abstract 137: Reversible Cerebral Vasoconstriction Syndrome due to Teprotumumab: Two Case Reports
Reversible Cerebral Vasoconstriction Syndrome (RCVS) is a rare, yet increasingly recognized condition characterized by segmental narrowing and dilation of cerebral vasculature. We present two novel cases of RCVS possibly linked to teprotumumab; a monoclonal antibody against insulin‐like growth factor 1 receptor (IGF‐1R) used in treating Graves’ eye disease (GED). The possible association between teprotumumab and RCVS prompts the need for increased awareness and further investigation.
Authors
- Mohammad Aladawi (ORCID: https://orcid.org/0000-0002-4884-1891)
- Zaid Najdawi (ORCID: https://orcid.org/0000-0002-1639-0758)
- Simon Phillips
- Kanchan Kumari (ORCID: https://orcid.org/0000-0001-5463-9764)
- Mithun G. Sattur (ORCID: https://orcid.org/0000-0002-2404-3780)
- Pashayar P. Lookian (ORCID: https://orcid.org/0000-0002-2436-9254)
- Mohamed Elfil (ORCID: https://orcid.org/0000-0002-1125-2946)
- Mark Jedras
Institutions
- Nebraska Medical Center (US)
- University of Miami (US)
- University of Alabama (US)
- Jackson Health System (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Stroke Vascular and Interventional Neurology
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1161/svin.04.suppl_1.137
- Primary Topic
- Neurological Complications and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.00